Phase I Study of Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Summary
The purpose of this open label, single institution, dose-escalation phase I study is to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled Drug Delivery (PEDD) technology. Oxaliplatin PEDD-PRVI is administered with systemic FOLFIRI followed by FOLFIRINOX therapy for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma.
General Information
NCT#: NCT04270929
Study ID: 342-30
Trial Phase: Phase I
Trial Sponsor: Roger Williams Medical Center, TriSalus Life Sciences
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, FOLFIRI, Pressure Enabled Drug Delivery - Pancreatic Retrograde Venous Infusion